Summary
The hepatobiliary pharmacokinetics of mitoxantrone, a new anthracenedione derivative, was studied in the isolated perfused rat liver. Mitoxantrone was administered in doses of 0.2 and 0.4 mg/kg body weight. Multiple bile samples were obtained for 4 hours. Mitoxantrone and three metabolites were separated by high-performance thin-layer chromatography (HPTLC) and measured at 610 nm.
Following 0.2 mg mitroxantrone/kg body wt, 25.8%±2.6% of the administered dose was excreted in the bile during 4 h, the major metabolite M1 accounting for 80% of this. After 0.4 mg mitoxantrone/kg body wt the amounts excreted were lower and light microscopic examination showed disseminated areas of cell necrosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alberts DS, Griffith KS, Goodman GE, Herman TS, Murray E (1980) Phase I clinical trial of mitoxantrone: A new anthracenedione anticancer drug. Cancer Chemother Pharmacol 5:11
Bock KW, Fröhling W, Schlote W (1972) Activity and stability of microsomal mixed function oxidase and NAD glycohydrolase in isolated perfused rat liver. Naunyn Schmiedebergs Arch Pharmacol 273:193
Goldsmith MA, Ohmura T, Roboz J, Jaffrey I, Greenspan EM, Holland JF (1981) Phase I clinical and pharmacological evaluation of mitoxantrone. Proc Am Soc Clin Oncol 22:389
Miller LL, Bly CG, Watson ML, Bale WF (1951) The dominant role of the liver in plasma protein synthesis. J Exp Med 94:431
Neidhard J, Staubus A, Young D, Malspeis L (1981) Pharmacokinetic studies of dihydroxyanthracenedione with clinical correlations. Proc Am Soc Clin Oncol 22:363
Ostroy F, Gams RA (1980) An HPLC method for the quantitative determination of 1,4-dihydroxy-5,8 bis ((2-((2-hydroxyethyl)amino)ethyl)amino)9,10-anthracenedione (DHAQ, Lederle Labs Cl 232 315, NCS 301739) in serum. J Liquid Chromatogr 3:637
Reynolds DL, Sternson LA, Repta A (1981) Clinical analysis for the anti-neoplastic agent 1,4-dihydroxy-5,8 bis ((2-((2-hydroxyethyl)amino)ethyl)amino)9,10-anthracenedione dihydrochloride (NSC 301739) in plasma. Application of temperature control to provide selectivity in paired-ion HPLC. J Chromatogr 22:225
Von Hoff DD, Pollard E, Kuhn J, Murray E, Coltman CA Jr (1980) Phase I clinical investigation of 1,4-dihydroxy-5,8 bis ((2-((2-hydroxyethyl)amino)ethyl)amino)9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione. Cancer Res 40:1516
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ehninger, G., Proksch, B., Hartmann, F. et al. Mitoxantrone metabolism in the isolated perfused rat liver. Cancer Chemother. Pharmacol. 12, 50–52 (1984). https://doi.org/10.1007/BF00255910
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00255910